Why Hims & Hers Health Stock Is Falling
Why Hims & Hers Health Stock Is Falling
为什么Hims & Hers Health股票在下跌
Eli Lilly and Co (NYSE:LLY) today announced an expansion in the availability of its obesity treatment, Zepbound (tirzepatide), which is now offered in 2.5 mg and 5 mg single-dose vials at a discounted price.
礼来（NYSE:LLY）今日宣布扩大其肥胖治疗药物Zepbound（替重匹肽）的可获性，现在以2.5毫克和5毫克单剂瓶以优惠价格提供。
The announcement has sent shockwaves through the telehealth and wellness industry, with Hims & Hers Health Inc (NYSE:HIMS) seeing a 5.05% drop to $15.24 during Tuesday's session amid possible competition concerns.
这一公告在远程健康和健康行业引起了轰动，Hims & Hers Health Inc（NYSE:HIMS）在周二的交易中看到股价下跌5.05%，至15.24美元，可能是因为竞争担忧。
Zepbound Enters the Market with Competitive Pricing: Lilly's new Zepbound single-dose vials are priced at a 50% or greater discount compared to other incretin (GLP-1) medicines for obesity, with a four-week supply of...
Zepbound以具有竞争力的定价进入市场：Lilly的新Zepbou...
登录免费看全文
登录/注册